Monodose versus 3 daily doses of sodium valproate: a controlled trial
Article first published online: 29 JAN 2009
Acta Neurologica Scandinavica
Volume 69, Issue 2, pages 120–124, February 1984
How to Cite
Gjerløff, I., Arentsen, J., Alving, J. and Secher, B. G. (1984), Monodose versus 3 daily doses of sodium valproate: a controlled trial. Acta Neurologica Scandinavica, 69: 120–124. doi: 10.1111/j.1600-0404.1984.tb07788.x
- Issue published online: 29 JAN 2009
- Article first published online: 29 JAN 2009
- Accepted for publication October 23, 1983
- plasma levels;
- seizure control;
- side effects;
- sodium valproate
ABSTRACT— 12 patients with absence epilepsy were treated with alternatively 1 or 3 daily doses of sodium valproate (VPA) in a double-blind cross-over design. Seizure frequency, EEG paroxysmal activity, clinical side-effects and laboratory findings were assessed for both treatment periods. There was no statistically significant difference between the 2 dosage schedules, and the simplicity of monodose treatment is an important factor in good patient compliance.
The apparent discrepancy between plasma half-life and biological action of VPA is discussed.